ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Trial Profile

ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Spartalizumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ElevatION
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Feb 2018 Status changed from active, no longer recruiting to recruiting.
    • 19 Feb 2018 Planned End Date changed from 7 Jan 2021 to 4 Jun 2019.
    • 19 Feb 2018 Planned primary completion date changed from 7 Jan 2021 to 4 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top